Please login to the form below

Not currently logged in
Email:
Password:

Advaxis

This page shows the latest Advaxis news and features for those working in and with pharma, biotech and healthcare.

Amgen enters into $540m immunotherapy collaboration

Amgen enters into $540m immunotherapy collaboration

For an upfront sum of $40m and $25m in Advaxis shares, the pharma giant receives exclusive global rights to develop and commercialise ADXS-NEO. ... Advaxis has long focused on the development of immuno-oncology therapies, and this partnership with Amgen

Latest news

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Acquisition - company. 705. Advaxis/ SELLAS Life Sciences Group. Advaxis' Lm-based antigen delivery technology with SELLAS’ WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S) (pre-clinical).

  • Deal Watch August 2016 Deal Watch August 2016

    624. Advaxis (US). Amgen (US). Licence. ADXS-NEO, preclinical investigational cancer immunotherapy treatment.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics